#read

BioNTech is expanding its lung cancer pipeline with new combinations

BioNTech is pursuing its clinical development in lung cancer in parallel using several therapeutic approaches. At the World Conference on Lung Cancer 2026 in Seoul, the Mainz-based company plans to present new data on Pumitamig, Gotistobart and an mRNA cancer immunotherapy. In total, the lung cancer programme comprises more than 16 ongoing clinical trials, including five Phase 3 trials.

20/08/2026

For the first time, particular focus is being placed on the combination of Pumitamig with Elfetabart Drozuntecan. Pumitamig is a bispecific immunomodulator that targets PD-L1 and VEGF. Elfetabart Drozuntecan is an antibody-drug conjugate targeting B7H3. Initial data from a global Phase 1 and 2 trial relate to both small-cell and non-small-cell lung cancer. In addition, BioNTech is presenting updated data on overall survival for Gotistobart in patients with advanced squamous cell lung cancer following prior immunotherapy. The second part of the Phase 3 PRESERVE 003 trial is ongoing and is relevant for regulatory approval. For the industry, the programme demonstrates how BioNTech is broadening its oncology strategy. In addition to mRNA, the company is now increasingly focusing on immunomodulators, antibody-drug conjugates and combinations of multiple mechanisms of action.

Press release from "BioNTech SE" dated 20 August 2026

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content